1. Home
  2. WKHS vs GRML Comparison

WKHS vs GRML Comparison

Compare WKHS & GRML Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Workhorse Group Inc.

WKHS

Workhorse Group Inc.

HOLD

Current Price

$3.26

Market Cap

33.7M

ML Signal

HOLD

Logo Greenland Mines Ltd. Common Stock

GRML

Greenland Mines Ltd. Common Stock

N/A

Current Price

$4.90

Market Cap

29.2M

Sector

N/A

ML Signal

N/A

Company Overview

Basic Information
Metric
WKHS
GRML
Founded
2007
N/A
Country
United States
United States
Employees
N/A
N/A
Industry
Auto Manufacturing
Sector
Consumer Discretionary
Exchange
Nasdaq
Nasdaq
Market Cap
33.7M
29.2M
IPO Year
2008
2022

Fundamental Metrics

Financial Performance
Metric
WKHS
GRML
Price
$3.26
$4.90
Analyst Decision
Hold
Analyst Count
1
0
Target Price
$21.00
N/A
AVG Volume (30 Days)
111.5K
6.1M
Earning Date
05-14-2026
05-13-2026
Dividend Yield
N/A
N/A
EPS Growth
86.92
31.25
EPS
N/A
N/A
Revenue
$763,173.00
N/A
Revenue This Year
$89.23
N/A
Revenue Next Year
$28.84
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$0.53
$0.16
52 Week High
$11.80
$11.66

Technical Indicators

Market Signals
Indicator
WKHS
GRML
Relative Strength Index (RSI) 53.22 61.91
Support Level $3.10 $0.20
Resistance Level $3.51 $11.66
Average True Range (ATR) 0.33 0.57
MACD 0.01 0.24
Stochastic Oscillator 34.90 41.14

Price Performance

Historical Comparison
WKHS
GRML

About WKHS Workhorse Group Inc.

Workhorse Group Inc is a technology company with a vision to pioneer the transition to zero-emission commercial vehicles. Its focus is to provide sustainable and cost-effective solutions to the commercial transportation sector. It designs and manufactures all-electric vehicles, including the technology that optimizes the way these vehicles operate. It's focused on a core competency of bringing electric delivery vehicle platforms to serve the last-mile delivery market. Its products are marketed under the Workhorse brand.

About GRML Greenland Mines Ltd. Common Stock

Greenland Mines Ltd develops essential medicines for the treatment of chronic diseases - cancer, cardiovascular, and neurodegenerative disorders. The Company operates as a single reporting segment focused on developing essential medicines for these chronic diseases. The Company has acquired two licensed platforms: a generic drug portfolio and a biosimilar biologics platform that uses biologic therapies to treat cancer, and proprietary patented technologies involving melanocortin receptor-binding molecules and a gene therapy platform that introduces a therapeutic protein called Klotho inside the body to treat neurodegenerative diseases.

Share on Social Networks: